CoChat
Sign Up
Cited by 335Attention Deficit Hyperactivity DisorderChild and Adolescent Psychosocial and Emotional DevelopmentSchizophrenia research and treatment

Effects of Risperidone on Conduct and Disruptive Behavior Disorders in Children With Subaverage IQs

SNYDER, RICHARD, TURGAY, ATILLA, AMAN, MICHAEL, BINDER, CARIN, FISMAN, SANDRA, CARROLL, ALLAN·2002·Journal of the American Academy of Child & Adolescent Psychiatry
DOI 10.1097/00004583-200209000-00002
Open this paper in CoChat — free account

Abstract

Objective To determine whether risperidone is effective in reducing symptoms of disruptive behaviors (such as aggression, impulsivity, defiance of authority figures, and property destruction) associated with conduct disorder, oppositional defiant disorder, and disruptive behavior disorder-not otherwise specified in children with subaverage IQs.Method The trial consisted of a 1-week, single-blind, placebo run-in period and was followed by a 6-week, double-blind, placebo-controlled period. One hundred ten children (aged 5-12 years inclusive) with an IQ of 36-84 with a disruptive behavior disorder and a score of at least 24 on the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (NCBRF) were enrolled. Eighty percent of subjects had comorbid attention-deficit/hyperactivity disorder (ADHD). Risperidone doses ranged from 0.02 to 0.06 mg/kg per day. Subjects were rated on the NCBRF, Aberrant Behavior Checklist, Behavior Problems Inventory, Clinical Global Impressions (CGI), modified California Verbal Learning Test (CVLT), and a continuous performance task (CPT).Results The intention-to-treat analysis of risperidone-treated subjects showed a significant (p < .001) reduction in mean scores (from 33.4 at baseline to 17.6 at end point; 47.3% reduction) versus placebo-treated subjects (mean baseline of 32.6 to 25.8 at end point; 20.9% reduction) on the Conduct Problem subscale of the NCBRF. Between-group differences in favor of risperidone were seen as early as week 1 and were significant at all post-baseline visits. Other subscales showed significant improvement with risperidone compared with placebo. CGI scale ratings of improvement showed highly significant gains for risperidone over placebo. A subanalysis demonstrated that the effect of risperidone was unaffected by diagnosis, presence/absence of ADHD, psychostimulant use, IQ status, and somnolence. Risperidone produced no changes on the cognitive variables (CPT/modified CVLT). The most common side effects included somnolence, headache, appetite increase, and dyspepsia. Side effects related to extrapyramidal symptoms were reported in 7 (13.2%) and 3 (5.3%) of the subjects in the risperidone and placebo groups, respectively (p = .245).Conclusions Risperidone appears to be an adequately tolerated and effective treatment in children with subaverage IQs and severe disruptive behaviors such as aggression and destructive behavior.

Integrity signals

Registry

Crossref · 10.1097/00004583-200209000-00002

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
SNYDER, R., TURGAY, A., AMAN, M., BINDER, C., FISMAN, S., & CARROLL, A.
Affiliations
University of Toronto (CA)
Corresponding author
AMAN, MICHAEL
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2002-09
Volume
41
Issue
9
Pages
1026-1036
ISSN
0890-8567 (ISSN-L)
DOI
10.1097/00004583-200209000-00002
OpenAlex
W2031582693
Cited by
335
References
39
Citations by year
2026: 3 · 2025: 1 · 2024: 8 · 2023: 4 · 2022: 10 · 2021: 8 · 2020: 5 · 2019: 2 · 2018: 4 · 2017: 9 · 2016: 7 · 2015: 10 · 2014: 14 · 2013: 21 · 2012: 17
FWCI
13.94
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
risperidone, conduct disorder, oppositional defiant disorder, disruptive behavior disorders, children with intellectual disabilities, aggression, impulsivity, ADHD comorbidity, antipsychotic drugs, extrapyramidal symptoms, sleepiness, cognitive function, Aberrant Behavior Checklist, continuous performance test
MeSH terms
Analysis of Variance, Child, Child, Preschool, Double-Blind Method, Female, Humans, Male, Intellectual Disability, Antipsychotic Agents, Single-Blind Method, Risperidone, Conduct Disorder, Attention Deficit and Disruptive Behavior Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review